- Home
- PRME vs UROY Comparison
PRME vs UROY Comparison
Compare PRME & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRME | UROY |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.1M | 513.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | UROY |
|---|---|---|
| Price | $4.01 | $3.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.31 | $4.50 |
| AVG Volume (30 Days) | ★ 3.8M | 2.0M |
| Earning Date | 11-07-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $5,977,000.00 | ★ $27,076,881.00 |
| Revenue This Year | $111.80 | $195.97 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1,392.79 |
| Revenue Growth | ★ 647.13 | N/A |
| 52 Week Low | $1.11 | $1.43 |
| 52 Week High | $6.94 | $5.37 |
Technical Indicators
Market Signals| Indicator | PRME | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 44.21 |
| Support Level | $3.95 | $3.52 |
| Resistance Level | $4.42 | $3.87 |
| Average True Range (ATR) | 0.31 | 0.20 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 65.09 | 21.19 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.